In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma

EMBO Molecular Medicine

Volumn 7, Issue 4, 2015, Pages 477-487

  Philipp Abbrederis, Kathrin ^a   Herrmann, Ken ^b   Knop, Stefan ^b   Schottelius, Margret ^a   Eiber, Matthias ^a   Lückerath, Katharina ^b   Pietschmann, Elke ^a   Habringer, Stefan ^a,c   Gerngroß, Carlos ^a   Franke, Katharina ^a   Rudelius, Martina ^b   Schirbel, Andreas ^b   Lapa, Constantin ^b   Schwamborn, Kristina ^a   Steidle, Sabine ^a   Hartmann, Elena ^b   Rosenwald, Andreas ^b   Kropf, Saskia ^d   Beer, Ambros J ^a,e   Peschel, Christian ^a,c   Einsele, Hermann ^b   Buck, Andreas K ^b   Schwaiger, Markus ^a,c   Götze, Katharina ^a,c   Wester, Hans Jürgen ^a,c,d   Keller, Ulrich ^a,c   more..

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d SCINTOMICS GMBH   (Germany)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

Chemokine receptor; CXCR4; in vivo imaging; Multiple myeloma; Positron emission tomography

Indexed keywords

CD34 ANTIBODY; CHEMOKINE RECEPTOR CXCR4; FLUORODEOXYGLUCOSE F 18; PENTIXAFOR GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CXCR4 PROTEIN, HUMAN; MOLECULAR PROBE; TUMOR PROTEIN;

ADULT; ADVANCED CANCER; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL COUNT; CD34 SELECTION; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FLOW CYTOMETRY; HUMAN; IN VIVO STUDY; MALE; MOLECULAR IMAGING; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; METABOLISM; MOLECULAR PROBE; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHARMACOLOGY; PROCEDURES; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED NOD; MOLECULAR IMAGING; MOLECULAR PROBES; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, CXCR4;

EID: 84926200332     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201404698     Document Type: Article

References (53)

1. Agarwal A, Chirindel A, Shah BA, Subramaniam RM (2013) Evolving role of FDG PET/CT in multiple myeloma imaging and management. AJR Am J Roentgenol 200: 884-890
2. Aggarwal R, Ghobrial IA, Roodman GD (2006) Chemokines in multiple myeloma. Exp Hematol 34: 1289-1295
3. Aiuti A, Turchetto L, Cota M, Cipponi A, Brambilla A, Arcelloni C, Paroni R, Vicenzi E, Bordignon C, Poli G (1999) Human CD34(+) cells express CXCR4 and its ligand stromal cell-derived factor-1. Implications for infection by T-cell tropic human immunodeficiency virus. Blood 94: 62-73
4. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM, Jia XY et al (2007) Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 109: 2708-2717
5. Angtuaco EJ, Fassas AB, Walker R, Sethi R, Barlogie B (2004) Multiple myeloma: clinical review and diagnostic imaging. Radiology 231: 11-23
6. Bao L, Lai YY, Liu YR, Qin YZ, Zhao XS, Lu XJ, Jiang Q, Lu J, Huang XJ (2013) CXCR4 is a good survival prognostic indicator in multiple myeloma patients. Leuk Res 37: 1083-1088
7. Baur-Melnyk A, Buhmann S, Durr HR, Reiser M (2005) Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 55: 56-63
8. Brave M, Farrell A, Ching Lin S, Ocheltree T, Pope Miksinski S, Lee SL, Saber H, Fourie J, Tornoe C, Booth B et al (2010) FDA review summary: mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology 78: 282-288
9. Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP (2003) Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 30: 917-920
10. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F (2009) The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 114: 3367-3375
11. Burger JA, Kipps TJ (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107: 1761-1767
12. Burger JA, Peled A (2009) CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23: 43-52
13. Cojoc M, Peitzsch C, Trautmann F, Polishchuk L, Telegeev GD, Dubrovska A (2013) Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. OncoTargets and Therapy 6: 1347-1361
14. Das T, Chakraborty S, Banerjee S, Venkatesh M (2007) On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor. Applied Radiation and Isotopes: Including Data, Instrumentation and Methods for use in Agriculture, Industry and Medicine 65: 301-308
15. De Silva RA, Peyre K, Pullambhatla M, Fox JJ, Pomper MG, Nimmagadda S (2011) Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J Nucl Med 52: 986-993
16. Demmer O, Gourni E, Schumacher U, Kessler H, Wester HJ (2011) PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem 6: 1789-1791
17. Drzezga A, Souvatzoglou M, Eiber M, Beer AJ, Furst S, Martinez-Moller A, Nekolla SG, Ziegler S, Ganter C, Rummeny EJ et al (2012) First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 53: 845-855
18. Durie BG, Waxman AD, D'Agnolo A, Williams CM (2002) Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 43: 1457-1463
19. Gourni E, Demmer O, Schottelius M, D'Alessandria C, Schulz S, Dijkgraaf I, Schumacher U, Schwaiger M, Kessler H, Wester HJ (2011) PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 52: 1803-1810
20. Graf N, Li Z, Herrmann K, Weh D, Aichler M, Slawska J, Walch A, Peschel C, Schwaiger M, Buck AK et al (2014) Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma. OncoTargets and Therapy 7: 789-798
21. Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Beuschlein F, Wangler B, Uebleis C, Schmidt GP, Spitzweg C, Bartenstein P et al (2014) Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. Radiology 270: 517-525
22. Honczarenko M, Douglas RS, Mathias C, Lee B, Ratajczak MZ, Silberstein LE (1999) SDF-1 responsiveness does not correlate with CXCR4 expression levels of developing human bone marrow B cells. Blood 94: 2990-2998
23. Ippolito D, Besostri V, Bonaffini PA, Rossini F, Di Lelio A, Sironi S (2013) Diagnostic value of whole-body low-dose computed tomography (WBLDCT) in bone lesions detection in patients with multiple myeloma (MM). Eur J Radiol 82: 2322-2327
24. Jacobson O, Weiss ID (2013) CXCR4 chemokine receptor overview: biology, pathology and applications in imaging and therapy. Theranostics 3: 1-2
25. Kashyap MK, Kumar D, Jones HJ, Choi MY, Melo-Cardenas J, Kuhne MR, Sabbatini P, Cohen L, Shelat S, Cardarelli PM et al (2012) BMS-936564 (MDX1338): a fully human anti-CXCR4 antibody induces apoptosis in an in vitro model of stromal - leukemia cell interaction for chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 2012 120: 2887
26. Kean LS, Sen S, Onabajo O, Singh K, Robertson J, Stempora L, Bonifacino AC, Metzger ME, Promislow DEL, Mattapallil JJ et al (2011) Significant mobilization of both conventional and regulatory T cells with AMD3100. Blood 118: 6580-6590
27. Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C, Chong CL, Cao F, Niekro W, Kempe T, Henning KA et al (2013) BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res 19: 357-366
28. Kuil J, Buckle T, van Leeuwen FWB (2012) Imaging agents for the chemokine receptor 4 (CXCR4). Chem Soc Rev 41: 5239-5261
29. Lückerath K, Lapa C, Spahmann A, Jorg G, Samnick S, Rosenwald A, Einsele H, Knop S, Buck AK (2013) Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology. PLoS ONE 8: e84840
30. Martin R, Juttler S, Muller M, Wester HJ (2014) Cationic eluate pretreatment for automated synthesis of [(6)(8)Ga]CPCR4.2. Nucl Med Biol 41: 84-89
31. Mendelson A, Frenette PS (2014) Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat Med 20: 833-846
32. Mirandola L, Apicella L, Colombo M, Yu Y, Berta DG, Platonova N, Lazzari E, Lancellotti M, Bulfamante G, Cobos E et al (2013) Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1. Leukemia 27: 1558-1566
33. Muller A, Homey B, Soto H, Ge NF, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56
34. Nimmagadda S, Pullambhatla M, Pomper MG (2009) Immunoimaging of CXCR4 Expression in Brain Tumor Xenografts Using SPECT/CT. J Nucl Med 50: 1124-1130
35. Nimmagadda S, Pullambhatla M, Stone K, Green G, Bhujwalla ZM, Pomper MG (2010) Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [Cu-64]AMD3100 positron emission tomography. Cancer Res 70: 3935-3944
36. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R et al (2014) New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 28: 525-542
37. Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364: 1046-1060
38. Parmo-Cabanas M, Bartolome RA, Wright N, Hidalgo A, Drager AM, Teixido J (2004) Integrin alpha 4 beta 1 involvement in stromal cell-derived factor-1 alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. Exp Cell Res 294: 571-580
39. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC (2009) Multiple myeloma. Lancet 374: 324-339
40. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D et al (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117: 4691-4695
41. Roodman GD (2010) Pathogenesis of myeloma bone disease. J Cell Biochem 109: 283-291
42. Shain KH, Tao J (2014) The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies. Oncogene 33: 4107-4113
43. Spano JP, Andre F, Morat L, Sabatier L, Besse B, Combadiere C, Deterre P, Martin A, Azorin J, Valeyre D et al (2004) Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 15: 613-617
44. Spoo AC, Lubbert M, Wierda WG, Burger JA (2007) CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 109: 786-791
45. Stessman HAF, Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB, Van Ness B (2013) Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia 27: 2075-2077
46. Teicher BA, Fricker SP (2010) CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16: 2927-2931
47. Weilbaecher KN, Guise TA, McCauley LK (2011) Cancer to bone: a fatal attraction. Nat Rev Cancer 11: 411-425
48. Weiss ID, Jacobson O (2013) Molecular Imaging of Chemokine Receptor CXCR4. Theranostics 3: 76-84
49. Werner RA, Bluemel C, Allen-Auerbach MS, Higuchi T, Herrmann K (2014) Gallium- and Yttrium-/Lutetium: "theranostic twins" for diagnosis and treatment of NETs. Ann Nucl Med 29: 1-7
50. Wester HJ, Keller U, Schottelius M, Beer AJ, Philipp-Abbrederis K, Hoffmann F, Šimeček J, Gerngross C, Lassmann M, Herrmann K, Pellegata N, Rudelius M, Kessler H, Schwaiger M (2015) Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics in press
51. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, Tacchetti P, Buttignol S, Perrone G, Brioli A et al (2011) Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118: 5989-5995
52. Zannettino ACW, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK, Diamond P, Tamamura H, Lapidot T, Fujii N et al (2005) Elevated serum levels of stromal-derived factor-1 alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 65: 1700-1709
53. Zlotnik A, Burkhardt AM, Homey B (2011) Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 11: 597-606